For early HER2-positive BC, T-DM1 is approved as adjuvant treatment in patients having residual invasive disease in the breast and/or lymph nodes after neoadjuvant treatment with at least a taxane and trastuzumab based treatment regimen as investigated in the KATHERINE trial [7]. This evidence concerns the gene ERBB2 and breast cancer.